Targeting a specific gene to treat ovarian cancer
Targeting MUC16 transactivation for ovarian cancer treatment
['FUNDING_R21'] · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · NIH-10544193
This study is exploring a new way to treat ovarian cancer by using a special virus that targets cancer cells, which could help boost the body's immune response and offer a better treatment option for patients.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE (nih funded) |
| Locations | 1 site (DUARTE, UNITED STATES) |
| Trial ID | NIH-10544193 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to treating ovarian cancer by focusing on the MUC16 gene, which is responsible for producing the CA-125 protein commonly found in high levels in ovarian cancer patients. The study aims to develop a specialized virus that can selectively replicate in ovarian cancer cells, potentially leading to a more effective treatment option. By targeting the unique characteristics of ovarian cancer cells, the research seeks to enhance the immune response against the cancer. Patients may benefit from this innovative treatment strategy if it proves successful.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with ovarian cancer who have elevated levels of CA-125.
Not a fit: Patients with ovarian cancer who do not express high levels of CA-125 or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, targeted treatment option for ovarian cancer patients, potentially improving survival rates.
How similar studies have performed: While targeting CA-125 has not been successful in the past, this approach of using a conditionally replicative adenovirus is novel and has not been extensively tested in this context.
Where this research is happening
DUARTE, UNITED STATES
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE — DUARTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, EDWARD WENGE — BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- Study coordinator: WANG, EDWARD WENGE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Antigen 125, Disease, Disorder